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Background: Human Cytomegalovirus (HCMV) infection has been reported to be a cause of refractory
ulcerative colitis (UC). Toxic megacolon (TM) is a rare but severe complication of an acute attack of UC.
Objectives: Aim of this study is to evaluate in a case-control study the association between HCMV and
TM.
Study design: All patients who were admitted at Medicine Department of V. Cervello Hospital in Palermo
(tertiary referral center) for a severe UC ﬂare-up complicated by the onset of TM (diameter of the trans-
verse colon>6 cm) between January 1990 and November 2011 were identiﬁed through the electronic
database. A total of 24 consecutive patients (16 male/8 female) with TM were identiﬁed. Each case of TM
were individually matched by sex, age, extent of the underlying disease to 24 severe UC controls who did
not develop TM. A further non matched control population of 48 severe UC was included.
Haematoxilin and eosin stain, immunohistochemical procedure and nested polymerase chain reac-
tion were performed to detect HCMV genes and proteins on rectal biopsies or surgical specimens. Pp65
antigenemia was performed in order to diagnose any possible systemic infection. HCMV frequency was
compared between patients with and without TM during follow-up, using Fisher’s Exact test.
Results and conclusions: HCMV was detected in histological specimens of 11 patients (46%) with TM
compared to 2 (9%) severe UC matched controls (P=0.0078) and 7 (14%) unmatched controls (p=0,003).
In severe colitis the presence of HCMV is more frequently associated with TM.
© 2015 Elsevier B.V. All rights reserved.
1. Background
TM is awell recognized, potentially fatal complication of UC and
denotes a clinical syndrome of systemic toxicity accompanied by
radiographic evidence of colonic dilatation. First described in 1950,
TM is a potentially lethal complication of inﬂammatory bowel dis-
ease (IBD) or infectious colitis, characterized by total or segmental
non-obstructive colonic dilatation of at least 6 cm associated with
systemic toxicity. Criteria for the diagnosis of TM in adults were
proposed by Jalan et al. [1].
Among infective cause Clostridium difﬁcile [3], Salmonella,
Shigella, Yersinia, Campylobacter and, above all in AIDS patients,
Cryptosporidium, Entameba and HCMV were recognized.
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A prospective study evaluated the prevalence rate of HCMV
infection among a population of consecutive IBD patients with
severe acute colitis, as well as the prevalence of this infection
among the subgroups of steroid refractory patients. The prevalence
ofHCMV infectionwas21% (9out of 42patients) [2]. Theprevalence
rate of HCMV infection in the steroid-refractory group was 33% (4
out of 12 patients) which approximate the previous estimate in a
previous series [3].
In one series, evidence of HCMV infection was found in the
resected colon of 6 of 46 patients with UC. Five of these six patients
but only 2 of the 40 patients without HCMV infection had TM [4].
Further cases reports described the association betweenHCMVand
TM [5–7] but it is not clear if HCMV is more frequent in TM than in
severe colitis.
http://dx.doi.org/10.1016/j.jcv.2015.03.009
1386-6532/© 2015 Elsevier B.V. All rights reserved.
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Table 1
Patient and disease characteristics of TM patients and control group.
TM patient Control matched Controls
Not matched
No. of patients (M/F) 24 (16/8) 24 (16/18) 48 (31/17)
Age at admission 45, 5 (15–70) 37, 4 (18–76) 39 (18–71)
Disease extent
# Pancolitis N. (%) 15 (62.5%) 14 (58%) 20 (41%)
# Left-sided N. (%) 9 (37.5%) 10 (42%) 28 (59%)
Steroid–dependance 11 (46%) 16 (66%) 15 (31%)
Previous therapy
Mesalamine 24 (100%) 24 (100%) 36 (100%)
Azathioprine 5 (21%) 13 (54%) 10 (20%)
2. Objectives
Aim of this study was to retrospectively assess the frequency of
HCMV infection in a consecutive series of severe UC complicated
by TM compared to a control group.
3. Study design
This was a retrospective study conducted in a single tertiary
referral center.
In our unit since 1975, all the patients admitted for severe ulcer-
ative colitis were evaluated clinically with the Truelove and Witts
criteria [8] and with a plain X-ray of the abdomen to evaluate
the diameter of the transverse colon. Patient was diagnosed to
have megacolon if the diameter of the transverse colon was >6 cm.
Patients during admission repeated plain X-ray of abdomen in rela-
tion to the clinical course.
Health records from 1990 to 2011 were electronically searched
through a database for patientswith the diagnosis of “megacolon”;
exclusion criteria were infectious or ischemic colitis, Hirschsprung
disease (HD) and the diagnosis of TM without a clear diagnosis of
IBD. Each case of TM were individually matched by sex, age, extent
of the underlying disease, year of onset of illness, to one severe
UC controls who during the clinical course did not develop TM. A
further control nonmatchedpopulation of 48 severeUCwas identi-
ﬁed from a cohort followed up from2000 to 2004 inwhich patients
matched with TM were excluded.
A total of 24 consecutive patients with TM (16 male/8 female;
median age at diagnosis 45, 5 years) were identiﬁed. The study
methodology was as follows: from 1990 to 1998 patients hospital-
ized for severe colitis underwent proctoscopy with rectal biopsy
without air insufﬂations in those who developed steroid resistance
after 5 days of conventional therapy. In case of megacolon proc-
toscopy was performed at diagnosis of this complication. From
1998 to 2011, patients underwent proctoscopy with rectal biopsy
at the ward admission without waiting for the response to steroid
therapy. Up to 1998 were identiﬁed a ﬁrst series of 11 patients, and
from 1999 to 2011 were identiﬁed a second series of 13 patients.
Basic characteristics, medication and disease history are listed in
Table 1.
Abdominal radiographs at the time of diagnosis with TM
and subsequent radiographs during that admission, were com-
pared with radiograph of the age-matched UC-controls and with
unmatched controls.
3.1. Laboratory techniques
Surgical specimens or rectal biopsies were evaluated by a ded-
icate pathologist in order to identify the presence of HCMV by
performing:
Table 2
Clinical characteristics and outcomes of patients with TM and HCMV+
Age/sex Relapse/onset Duration of
disease (year)
Extent of disease Outcome
1 F/53 R 31 P C
2 M/48 R 16 T C
3 M/63 O 0 P C/E
4 M/45 O 0 P C/E
5 F/75 R 20 P E
6 F/70 R 11 T A
7 M/46 R 16 L C
8 M/17 R 2 P C
9 M/22 R 8 P C
10 M/55 R 11 P C
11 M/32 R 2 P C
#P=pancolitis, T = transverse, L = left colitis, §C= colectomy, A= antiviral therapy,
E = exitus
• Light microscopy with Haematoxilin and Eosin (H&E) stain in
order to document themicroscopic disease activity and allow the
detection of cytomegalic cells, markers of infected viral cells.
• Immunohistochemical (ICH) procedure for HCMV performed on
a parafﬁn-embedded section with monoclonal mouse antibodies
anti-HumanCMV (clone BM204) and conjugated to a peroxidase-
labeled amino acid polymer by peroxidase-antiperoxidase (PAP)
method in order to detect viral proteins. Nuclear or cytoplasmic
antigen was identiﬁed by the typical brown reaction product of
the PAP method.
• Nested polymerase chain reaction (nPCR) by using two pairs of
primers annealed to the gB region of HCMV. Primers used for the
ﬁrst-roundproduct and second-roundPCRs are as follows (5′–3′):
ﬁrst-round primer 1, GAGGACAACGAAATCCTGTTGGGCA; ﬁrst-
round primer 2, GTCGACGGTGGAGATACTGCTGAGG; second-
round primer 3, ACCACCGCACTGsAGGAATGTCAG; and second-
round primer 4, TCAATCATGCGTTTGAAGAGGTA, to obtain a
HCMV fragment of 100bp.
The PCR ampliﬁcation products were run on 2% agarose gel and
stained with ethidium bromide and visualized under ultraviolet
light.
On peripheral blood was also performed:
• Pp65 antigenemia consist of the detection of the viral pp65
tegumentproteinby immunoﬂuorescence inpolymorphonuclear
neutrophils (PNML), previously recovered from a blood buffy-
coat. The result was expressed as the number of positive cells
per 200.000 PNML.
3.2. Statistical analysis
Presence of HCMV were compared between patients with TM
and2 controls population, using chi-square statistics, Fisher’s Exact
test. Data were analyzed using the software package SPSS 15150
(SPSS Inc., Chicago, IL, USA).
4. Results
Among the 24 patients identiﬁed in the series, HCMV was
detected in histological specimens of 11 patients (46%) (Table 2)
with severe UC complicated with TM, compared to 2 (9%) matched
controls (P=0.0078) and 7 (14%) (p=0,003) unmatched controls.
Among the TM HCMV+patients, the virus was identiﬁed in rec-
tal biopsies in seven and in surgical specimen in four. The rate of
steroid-resistance in patients with TM was 45% (5/11) among the
ﬁrst series and 53% (7/13) among the second series. Steroid resis-
tance was 21% among matched (5/24) and 20% (10/48) among un
matched controls.
V. Criscuoli et al. / Journal of Clinical Virology 66 (2015) 103–106 105
Table 3
Comparison between the various diagnostic techniques.
Cases Matched Controls Unmatched
HCMV-DNA+ (qualitative) 11 2 7
H&O stain 7 2 7
ICH 7 2 7
Pp65 antigen 8 2 0
HCMV was identiﬁed with H&E stain in 7 and with PCR in 11
patents with TM; among the matched control population HCMV
was identiﬁed with H&E stain and with PCR in 2 patients and
among unmatched controls in 7 patients, respectively (Table 3).
Systemic infection was identiﬁed in 8 patients with megacolon,
in 2 patients among matched controls. No systemic infection was
observed among unmatched controls.
In the TM group, 20 of 24 (83%) patients underwent colec-
tomy during the hospitalization, compared with 4 of 24 (18%)
matched controls (P=0.0001) and 0/36 among the unmatched con-
trols. Among 11 TM HCMV positive patients 9 were operated on
compared to 11 TM HCMV negative patients, showing a not statis-
tically signiﬁcant result. Among the TM patients HCMV+, 3 patients
died during the hospitalization due to the worsening of clinical
conditions.
Colectomy was performed in the control patients due to failure
of intravenous corticosteroid therapy, and in one case due to fail-
ure of rescue therapy as Inﬂiximab. All patients with HCMV except
one were treated with anti-viral drugs. Among MT patients with
HCMV, only 1 patients responded (treatedwithVanganciclovir [9]).
Among the 2 control groups, 7 patients with HMCV were treated
with Ganciclovir, one with Foscarnet and one was not treated. Only
one patient did not respond and was operated on.
5. Discussion
This paper shows that there was a signiﬁcant higher incidence
of HCMV infection in the colon of patients with UC complicated by
TM, suggesting a possible role of this viral infection in precipitating
this condition.
The results are hampered from the fact that the search forHCMV
was more extensive in those operated on but if we exclude those
in which the virus was detected in the surgical specimens the dif-
ference was still signiﬁcant. Furthermore, the retrospective nature
of the study may weakens the conclusions; TM is a rare condition
and prospective studies are difﬁcult to set up and require the par-
ticipation of many center for a long period of time. In order to give
strength to the results, we evaluated 2 types of controls (matched
and unmatched) because it was difﬁcult to ﬁnd matched controls.
In the literature, many single cases [10–12] and 3 small series
of TM [13–14] associated to HCMV are reported. Cooper et al. [4]
detected HCMV infection in the resected colon of 6 of 46 patients
with UC. Five of these six patients but only 2 of the 40 patients
withoutHCMV infectionhadTM,whereas Eyre-Brooket al. [15] and
Barahona-Garrido et al. [16] did not show evidence for HCMV in 3
patients with TM and a low prevalence in 47 patients operated on
for colectomy, respectively. The reasonwhyHCMVismore frequent
in TM is quite uncertain.
The only possible risk factor for superimposed HCMV infection
is previous immunosuppression [17], but in our series patientswho
developed TM had a lower rate of immunosuppressive therapy
before admission.
One could make the hypothesis of a role of the virus on the
ganglionic cells like in HD where congenital HCMV infection is cor-
related with development of the disease. Multiple strains of virus
circulate both within the population and within an individual, and
evidence exists for inter-strain recombination [18–19]. There are
no data on the genetic variants of HCMV in IBD.
It is not clear if the use of antiviral therapy determines a regres-
sion of TM. We reported a case [9] which show a response to oral
Valgangiclovir with regression of colonic dilatation suggesting a
possible role of this therapy, but the single case is not sufﬁcient to
draw any conclusion. The risk and beneﬁts of HCMV anti-viral ther-
apy need to be considered before decisions and are taken according
to clinical conditions and viral load detected by molecular diag-
nostic techniques such as nPCR. HCMV anti-viral drugs have the
potential for serious side effects, including bone marrow suppres-
sion, pulmonary and neurological dysfunction; so robust evidence
of beneﬁt is needed.
TM is a rapid progressive complication and it is difﬁcult to state
that antiviral therapy is able in few days to reverse this condition.
Our paper does not show an increased risk of surgery for those
with HCMV indicating that the possible treatment of the virus does
not seem to be relevant in a brief term period.
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